Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jul 22, 2025 | Aristotle International Equity Fund | 10.7% | 14.6% | 4578.T, 6758.T, 7532.T, ACN, ALC, CCO.TO, EBS.VI, MC.PA, SAF.PA | aerospace, Asia, Europe, international, Luxury, nuclear, Quality, Trade Policy | Trade policy remained a focal point with President Trump introducing a universal 10% import tariff and reciprocal tariffs on dozens of countries. A 90-day pause on reciprocal tariffs was enacted for almost all countries, and the U.S. and U.K. finalized the Economic Prosperity Deal. Major economies experienced downward revisions to 2025 GDP growth projections due to trade policy uncertainty. | SAF.PA CCO.TO MC.PA ALC SAF FP MC FP ALC SW |
View |
| 2026 Q1 | May 1, 2026 | Aristotle International Equity Fund | -3.3% | -3.3% | 0669 HK, 3064.T, 4578.T, BN, TTE | energy, Geopolitical, healthcare, international, long-term, Quality, value | 0669.HK BN 3064.T 4578.T TTE |
View | |
| 2026 Q1 | May 1, 2026 | Aristotle/Saul Global Equity Fund | -2.4% | -2.4% | 3064.T, 4578.T, CVX, QCOM, TTE | energy, global, healthcare, long-term, technology, value | CVX QCOM 3064.T 4578.T TTE |
View | |
| 2024 Q3 | Sep 30, 2024 | Aristotle International Equity Fund | 10.5% | 13.3% | 005930.KS, 3064.T, 4578.T, 6758.T, 7532.T, 9433.T, ACN, AHT.L, BN, CCO, DEO, GSK, HEIA.AS, NEM.DE, ROG.SW, RTO.L, SAF.PA, TTE | Asia, Diversified, Europe, international, Quality, value | MonotaRO operates a B2B e-commerce platform selling 20 million items to over 8 million customers, primarily in Japan. The company serves as a one-stop solution with transparent pricing and same-day shipment capabilities. Its unique profile with over 95% of sales online provides customers a distinct value proposition in the fragmented MRO market. | 3064.T DGE.L 9681.T RTO.L BN.TO |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Fund Letters | Aristotle/Saul Global Equity Fund | Otsuka Holdings | Drug Manufacturers - General | Pharmaceuticals | Bull | New York Stock Exchange | Abilify, Colorectal Cancer, Depression, Japan, Oncology, pharmaceuticals, pipeline, Psychiatry, PTSD, Rexulti, Schizophrenia, Share Buyback | View Pitch |
| May 4, 2026 | Fund Letters | Aristotle International Equity Fund | Otsuka Holdings | Drug Manufacturers - General | Pharmaceuticals | Bull | New York Stock Exchange | Depression, innovation, Japan, Mental health, Oncology, pharmaceuticals, pipeline, PTSD, Schizophrenia, Share Buyback | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||